Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Research & Development (2022 - 2025)

Zentalis Pharmaceuticals has reported Research & Development over the past 4 years, most recently at $29.5 million for Q4 2025.

  • Quarterly results put Research & Development at $29.5 million for Q4 2025, down 10.57% from a year ago — trailing twelve months through Dec 2025 was $107.3 million (down 36.05% YoY), and the annual figure for FY2025 was $107.3 million, down 36.05%.
  • Research & Development for Q4 2025 was $29.5 million at Zentalis Pharmaceuticals, up from $23.0 million in the prior quarter.
  • Over the last five years, Research & Development for ZNTL hit a ceiling of $51.6 million in Q4 2023 and a floor of $23.0 million in Q3 2025.
  • Median Research & Development over the past 4 years was $42.4 million (2022), compared with a mean of $39.8 million.
  • Biggest five-year swings in Research & Development: grew 26.94% in 2023 and later tumbled 45.05% in 2025.
  • Zentalis Pharmaceuticals' Research & Development stood at $40.6 million in 2022, then grew by 26.94% to $51.6 million in 2023, then tumbled by 36.05% to $33.0 million in 2024, then decreased by 10.57% to $29.5 million in 2025.
  • The last three reported values for Research & Development were $29.5 million (Q4 2025), $23.0 million (Q3 2025), and $27.6 million (Q2 2025) per Business Quant data.